Amundi Fate Therapeutics Inc Transaction History

Amundi

  • $264 Billion
  • Q3 2024

A detailed history of Amundi transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Amundi holds 4,990 shares of FATE stock, worth $8,283. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,990
Previous 4,990 -0.0%
Holding current value
$8,283
Previous $16,000 6.25%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$3.26 - $7.08 $16,267 - $35,329
4,990 New
4,990 $16,000
Q1 2023

May 15, 2023
SELL
$4.24 - $11.12 $19,775 - $51,863
-4,664 Reduced 39.47%
7,154 $40,000
Q4 2022

Feb 14, 2023
SELL
$9.86 - $23.83 $690,495 - $1.67 Million
-70,030 Reduced 85.56%
11,818 $119,000
Q3 2022

Nov 14, 2022
SELL
$21.04 - $36.06 $3.24 Million - $5.55 Million
-153,845 Reduced 65.27%
81,848 $1.93 Million
Q2 2022

Aug 15, 2022
SELL
$17.78 - $42.39 $2.17 Million - $5.17 Million
-121,846 Reduced 34.08%
235,693 $7.43 Million
Q1 2022

May 16, 2022
SELL
$29.67 - $60.28 $700,063 - $1.42 Million
-23,595 Reduced 6.19%
357,539 $14.1 Million
Q4 2021

Feb 14, 2022
SELL
$47.84 - $64.34 $885,996 - $1.19 Million
-18,520 Reduced 4.63%
381,134 $16.1 Million
Q3 2021

Nov 15, 2021
SELL
$59.27 - $95.73 $523,531 - $845,583
-8,833 Reduced 2.16%
399,654 $23.7 Million
Q2 2021

Aug 16, 2021
BUY
$67.25 - $92.52 $27.5 Million - $37.8 Million
408,487 New
408,487 $35.5 Million

Others Institutions Holding FATE

# of Institutions
175
Shares Held
115M
Call Options Held
53.7K
Put Options Held
9K
View Full List

About FATE THERAPEUTICS INC

FATE Quotes by TradingView
  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $161M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Amundi Portfolio

Follow Amundi and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

News

Stay updated on Amundi with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email